252 related articles for article (PubMed ID: 29088978)
1. The biological challenges and pharmacological opportunities of orally administered nanomedicine delivery.
Moss DM; Curley P; Kinvig H; Hoskins C; Owen A
Expert Rev Gastroenterol Hepatol; 2018 Mar; 12(3):223-236. PubMed ID: 29088978
[TBL] [Abstract][Full Text] [Related]
2. Oral drug delivery with nanoparticles into the gastrointestinal mucosa.
Liu J; Leng P; Liu Y
Fundam Clin Pharmacol; 2021 Feb; 35(1):86-96. PubMed ID: 32749731
[TBL] [Abstract][Full Text] [Related]
3. Models and methods to evaluate transport of drug delivery systems across cellular barriers.
Ghaffarian R; Muro S
J Vis Exp; 2013 Oct; (80):e50638. PubMed ID: 24192611
[TBL] [Abstract][Full Text] [Related]
4. Oral absorption of peptides and nanoparticles across the human intestine: Opportunities, limitations and studies in human tissues.
Lundquist P; Artursson P
Adv Drug Deliv Rev; 2016 Nov; 106(Pt B):256-276. PubMed ID: 27496705
[TBL] [Abstract][Full Text] [Related]
5. Nanomedicines for intranasal delivery: understanding the nano-bio interactions at the nasal mucus-mucosal barrier.
Hua T; Li S; Han B
Expert Opin Drug Deliv; 2024 Apr; 21(4):553-572. PubMed ID: 38720439
[TBL] [Abstract][Full Text] [Related]
6. Delivery of Orally Administered Digestible Antibodies Using Nanoparticles.
Tashima T
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33805888
[TBL] [Abstract][Full Text] [Related]
7. Anionic nanoparticles enable the oral delivery of proteins by enhancing intestinal permeability.
Lamson NG; Berger A; Fein KC; Whitehead KA
Nat Biomed Eng; 2020 Jan; 4(1):84-96. PubMed ID: 31686002
[TBL] [Abstract][Full Text] [Related]
8. Lessons from nature: "Pathogen-Mimetic" systems for mucosal nano-medicines.
Mrsny RJ
Adv Drug Deliv Rev; 2009 Feb; 61(2):172-92. PubMed ID: 19146895
[TBL] [Abstract][Full Text] [Related]
9. Cellular uptake and transcytosis of lipid-based nanoparticles across the intestinal barrier: Relevance for oral drug delivery.
Neves AR; Queiroz JF; Costa Lima SA; Figueiredo F; Fernandes R; Reis S
J Colloid Interface Sci; 2016 Feb; 463():258-65. PubMed ID: 26550783
[TBL] [Abstract][Full Text] [Related]
10. Improved transport and absorption through gastrointestinal tract by PEGylated solid lipid nanoparticles.
Yuan H; Chen CY; Chai GH; Du YZ; Hu FQ
Mol Pharm; 2013 May; 10(5):1865-73. PubMed ID: 23495754
[TBL] [Abstract][Full Text] [Related]
11. Development and in vivo evaluation of papain-functionalized nanoparticles.
Müller C; Perera G; König V; Bernkop-Schnürch A
Eur J Pharm Biopharm; 2014 May; 87(1):125-31. PubMed ID: 24373995
[TBL] [Abstract][Full Text] [Related]
12. Effect of surface chemistry on nanoparticle interaction with gastrointestinal mucus and distribution in the gastrointestinal tract following oral and rectal administration in the mouse.
Maisel K; Ensign L; Reddy M; Cone R; Hanes J
J Control Release; 2015 Jan; 197():48-57. PubMed ID: 25449804
[TBL] [Abstract][Full Text] [Related]
13. Recent Advances in Oral Nano-Antibiotics for Bacterial Infection Therapy.
Wu ZL; Zhao J; Xu R
Int J Nanomedicine; 2020; 15():9587-9610. PubMed ID: 33293809
[TBL] [Abstract][Full Text] [Related]
14. Intestinal mucosa permeability following oral insulin delivery using core shell corona nanolipoparticles.
Li X; Guo S; Zhu C; Zhu Q; Gan Y; Rantanen J; Rahbek UL; Hovgaard L; Yang M
Biomaterials; 2013 Dec; 34(37):9678-87. PubMed ID: 24016855
[TBL] [Abstract][Full Text] [Related]
15. Role of the Basement Membrane as an Intestinal Barrier to Absorption of Macromolecules and Nanoparticles.
Mantaj J; Abu-Shams T; Enlo-Scott Z; Swedrowska M; Vllasaliu D
Mol Pharm; 2018 Dec; 15(12):5802-5808. PubMed ID: 30380896
[TBL] [Abstract][Full Text] [Related]
16. Addressing the challenges to increase the efficiency of translating nanomedicine formulations to patients.
Bhattacharjee S; Brayden DJ
Expert Opin Drug Discov; 2021 Mar; 16(3):235-254. PubMed ID: 33108229
[TBL] [Abstract][Full Text] [Related]
17. Site of drug absorption after oral administration: assessment of membrane permeability and luminal concentration of drugs in each segment of gastrointestinal tract.
Masaoka Y; Tanaka Y; Kataoka M; Sakuma S; Yamashita S
Eur J Pharm Sci; 2006 Nov; 29(3-4):240-50. PubMed ID: 16876987
[TBL] [Abstract][Full Text] [Related]
18. Exploiting disease-induced changes for targeted oral delivery of biologics and nanomedicines in inflammatory bowel disease.
Zhang Y; Thanou M; Vllasaliu D
Eur J Pharm Biopharm; 2020 Oct; 155():128-138. PubMed ID: 32853696
[TBL] [Abstract][Full Text] [Related]
19. Avoiding a Sticky Situation: Bypassing the Mucus Barrier for Improved Local Drug Delivery.
Zierden HC; Josyula A; Shapiro RL; Hsueh HT; Hanes J; Ensign LM
Trends Mol Med; 2021 May; 27(5):436-450. PubMed ID: 33414070
[TBL] [Abstract][Full Text] [Related]
20. Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers.
Ensign LM; Cone R; Hanes J
Adv Drug Deliv Rev; 2012 May; 64(6):557-70. PubMed ID: 22212900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
